Accessibility Menu
Aprea Therapeutics Stock Quote

Aprea Therapeutics (NASDAQ: APRE)

$1.51
(-8.5%)
-0.14
Price as of October 21, 2025, 3:59 p.m. ET

KEY DATA POINTS

Current Price
$1.51
Daily Change
(-8.5%) $0.14
Day's Range
$1.43 - $1.64
Previous Close
$1.51
Open
$1.64
Beta
-0.97
Volume
287,619
Average Volume
61,373
Market Cap
9.6M
Market Cap / Employee
$1.65M
52wk Range
$1.37 - $5
Revenue
-
Gross Margin
0.97%
Dividend Yield
N/A
EPS
-$2.31
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Aprea Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
APRE-64.88%-99.72%-69.05%-88%
S&P+14.84%+96.04%+14.41%+65%

Aprea Therapeutics Company Info

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Financial Health

General

Q2 2025YOY Change
Revenue$0.12M-79.0%
Gross Profit$0.11M-79.7%
Gross Margin95.40%-3.7%
Market Cap$9.35M-57.7%
Market Cap / Employee$1.17M0.0%
Employees814.3%
Net Income-$3.24M6.7%
EBITDA-$3.38M12.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$16.53M-42.4%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.00M0.0%
Short Term Debt$0.00M0.0%

Ratios

Q2 2025YOY Change
Return On Assets-58.59%-14.5%
Return On Invested Capital-140.61%-8.1%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$3.48M1.8%
Operating Free Cash Flow-$3.48M1.6%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.580.810.580.60-21.59%
Price to Sales12.4613.049.5212.22-35.47%
Price to Tangible Book Value0.580.810.580.60-21.59%
Enterprise Value to EBITDA2.100.601.411.6394.92%
Return on Equity-60.2%-66.7%-59.8%-67.5%34.79%
Total Debt$0.00M$0.00M$0.00M$0.00M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.